| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | KCNK9 |
| Uniprot No | Q9NPC2 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-374aa |
| 氨基酸序列 | MKRQNVRTLSLIVCTFTYLLVGAAVFDALESDHEMREEEKLKAEEIRIKGKYNISSEDYRQLELVILQSEPHRAGVQWKFAGSFYFAITVITTIGYGHAAPGTDAGKAFCMFYAVLGIPLTLVMFQSLGERMNTFVRYLLKRIKKCCGMRNTDVSMENMVTVGFFSCMGTLCIGAAAFSQCEEWSFFHAYYYCFITLTTIGFGDYVALQTKGALQKKPLYVAFSFMYILVGLTVIGAFLNLVVLRFLTMNSEDERRDAEERASLAGNRNSMVIHIPEEPRPSRPRYKADVPDLQSVCSCTCYRSQDYGGRSVAPQNSFSAKLAPHYFHSISYKIEEISPSTLKNSLFPSPISSISPGLHSFTDHQRLMKRRKSV |
| 预测分子量 | 48.3 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3条关于KCNK9重组蛋白的参考文献及其摘要内容的简要概括：
1. **"Structural basis for pH gating of the two-pore domain K⁺ channel TASK-2"**
- 作者：M. Lolicato 等 (2021)
- 摘要：通过冷冻电镜解析了人源KCNK9(TASK-3)重组蛋白的分子结构，揭示了其pH敏感性门控机制及与癌症相关突变的作用位点，为靶向药物设计提供结构基础。
2. **"KCNK9 overexpression is associated with breast cancer progression and predicts poor survival"**
- 作者：A. Muñoz 等 (2018)
- 摘要：利用重组KCNK9蛋白研究其在乳腺癌细胞中的过表达机制，发现其通过调控细胞增殖和迁移促进肿瘤侵袭，提出KCNK9作为潜在预后标志物。
3. **"Functional characterization of TASK-3 potassium channels in neuroendocrine cells"**
- 作者：S. G. Aller 等 (2015)
- 摘要：通过重组KCNK9蛋白表达系统，分析其在神经元和内分泌细胞中的电生理特性，证明其通过调节静息膜电位影响神经信号传导及激素分泌。
**Background of KCNK9 Recombinant Protein**
KCNK9. also known as TASK-3 (TWIK-related acid-sensitive K⁺ channel 3), is a member of the two-pore domain potassium (K₂P) channel family. These channels regulate cellular resting membrane potential and contribute to action potential repolarization, playing critical roles in maintaining physiological homeostasis. KCNK9 forms weakly rectifying, voltage-independent K⁺ channels that are sensitive to extracellular pH, hypoxia, and neurotransmitters. Structurally, it contains two pore-forming domains (4 transmembrane segments each) and functions as a dimer or tetramer, often partnering with related channels like TASK-1 (KCNK3).
KCNK9 is predominantly expressed in the central nervous system, heart, adrenal glands, and placenta. Its activity influences neuronal excitability, hormone secretion, and cardioprotection. Dysregulation of KCNK9 is linked to pathologies, including cancer (e.g., breast, lung), developmental disorders (e.g., Birk-Barel syndrome), and neurological conditions. Notably, KCNK9 is an imprinted gene, with maternal alleles preferentially expressed in specific brain regions, and mutations (e.g., Gly236Arg) can disrupt channel function, leading to neurodevelopmental impairments.
Recombinant KCNK9 protein is produced via heterologous expression systems (e.g., mammalian or insect cells) to study its biophysical properties, regulatory mechanisms, and interactions. Purified recombinant proteins often include tags (e.g., His-tag) for affinity chromatography. These tools enable drug screening, structure-function analyses, and exploration of its roles in disease. Research on KCNK9 recombinant proteins aids in developing modulators targeting K⁺ channels for therapeutic interventions in cancer, neurological disorders, and cardiovascular diseases.
×
